The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries | |
Sun, Guo-ping; Sun, Yan; Xu, Rui-hua; Xu, Jian-Ming; Li, Jin; Wang, Jin-Wan; Qin, Shukui; Feng, Ji Feng; Ba, Yi; Shen, Lin | |
2013 | |
会议名称 | JOURNAL OF CLINICAL ONCOLOGY |
会议日期 | 2013-05-20 |
收录类别 | CPCI-S |
URL标识 | 查看原文 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6687679 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Sun, Guo-ping,Sun, Yan,Xu, Rui-hua,et al. The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2013-05-20. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论